医薬品中間体の世界市場 - 市場規模、シェア、成長分析：、製品別（化学中間体、原薬中間体）、用途別（鎮痛薬、抗炎症薬） - 業界予測（2023年～2030年）

世界の医薬品中間体の市場規模は、2021年に290億米ドル、2022年に306億米ドルとなりました。同市場は、予測期間中（2023年～2030年）に6.3%のCAGRで拡大し、2030年には526億米ドルに拡大すると予測されています。

医薬品中間体は、原薬製造の原料として重要な役割を果たしています。これらの中間体は、さらに加工する前の医薬品有効成分（API）の合成中に形成されます。これらの中間体は高品質の基本成分から作られ、医薬品産業や化粧品産業で幅広く利用されています。世界の医薬品中間体市場は、特に研究開発目的のこれらの分野における需要の高まりにより成長を経験しています。

慢性疾患の有病率の上昇と世界の高齢化は、これらの病態を管理するための薬剤製剤の需要増加に寄与する重要な要因です。世界保健機関（WHO）によると、糖尿病の患者数は1980年の1億800万人から2014年には4億2,200万人に増加し、増加傾向が続いています。さらにWHOは、2020年までに慢性疾患の発症率が57%増加すると予測しており、人口のかなりの部分がこれらの疾患の影響を受けていることを意味しています。その結果、医薬品市場は、これらの促進要因によって予測期間中に成長を示しています。

世界の医薬品中間体市場は、2つの重要な要因によって成長の課題に直面しています。第一に、バイオ医薬品の入手に伴う高額な費用が大きな障害となっています。第二に、医薬品原薬（API）の生産に必要な多額の設備投資が、市場の成長を阻害する重大な要因となっています。

当レポートは、世界の医薬品中間体市場について調査し、市場の概要とともに、製品別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査手法

親市場分析

• 市場概要
• 市場規模
• 市場力学

主要な市場洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• 知財分析
• 貿易分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品の分析
• マクロ経済指標
• トップの投資分析
• 主要な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• 規制状況
• ポーターズ分析

世界の医薬品中間体市場、製品別

• 市場概要
• 化学中間体
• 原薬中間体
• およびカスタム中間体

世界の医薬品中間体市場、用途別

• 市場概要
• 鎮痛剤
• 抗炎症薬
• 心臓血管薬
• 抗糖尿病薬
• 抗癌剤

世界の医薬品中間体市場規模、地域別

• 市場概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

競合情勢

主要企業プロファイル

• BASF SE
• Lonza Group AG
• Thermo Fisher Scientific Inc.
• Wuxi AppTec Co. Ltd.
• Merck KGaA
• Dishman Group
• Codexis Inc.
• Cambrex Corporation
• Hikal Ltd.
• Chemcon Speciality Chemicals Ltd.
• Porton Fine Chemicals Ltd.
• Divis Laboratories Ltd.
• Pfizer CentreOne
• Aurobindo Pharma Ltd.
• Sanofi SA
• Lianhe Chemical Technology Co. Ltd.
• Jiangsu Hengrui Medicine Co. Ltd.
• Shandong Xinhua Pharmaceutical Co. Ltd.
• WuXi STA
• Zhejiang NHU Co. Ltd.

Global Pharmaceutical Intermediates Market size was valued at USD 29 billion in 2021 and is poised to grow from USD 30.6 billion in 2022 to USD 52.6 billion by 2030, growing at a CAGR of 6.3% in the forecast period (2023-2030).

Pharmaceutical intermediates play a crucial role as raw materials in the production of bulk drugs. These intermediates are formed during the synthesis of active pharmaceutical ingredients (APIs) before further processing. They are derived from high-quality basic ingredients and find extensive applications in the pharmaceutical and cosmetic industries. The global market for pharmaceutical intermediates is experiencing growth due to the rising demand in these sectors, particularly for research and development purposes.

These intermediates are essential in the manufacturing of various products, including pesticides, drugs, resins, additives, plasticizers, and more, using materials like coal tar or petroleum. The market's expansion is primarily driven by the increased production of active pharmaceutical ingredients, responding to the growing demand for advanced therapies with improved delivery systems and personalized medicines worldwide.

Despite the positive outlook, the industry faces challenges such as the high cost of acquiring biopharmaceutical drugs and substantial apital investments required for API production. However, the introduction of new technologies in pharmaceutical manufacturing and increased investment in research activities are expected to create promising growth opportunities in the coming years.

Segments covered in this report:

Global pharmaceutical intermediates market is segmented on the basis of product, application, and region. On the basis of product, global market is segmented into chemical intermediates, bulk drug intermediates and custom intermediates. On the basis of application, global market is segmented into, analgesics, anti-inflammatory drug, cardiovascular drugs, anti-diabetic drugs and anti-cancer drugs. On the basis of region, global market is divided into North America, Europe, Asia Pacific, Latin America, and MEA.

Driver

The rising prevalence of chronic diseases and the global aging population are significant factors contributing to an increased demand for drug formulations to manage these conditions. According to the World Health Organization (WHO), the cases of diabetes have escalated from 108.0 million in 1980 to 422.0 million in 2014, with a continuous upward trend. Additionally, the WHO predicts a 57% increase in the incidence of chronic diseases by 2020, signifying a substantial portion of the population being affected by these conditions. As a result, the pharmaceutical market is witnessing growth during the forecast period due to these driving factors.

Restraint

The global pharmaceutical intermediates market faces challenges to its growth due to two significant factors. Firstly, the high expenses associated with acquiring biopharmaceutical drugs act as a major hindrance. Secondly, the substantial capital investment required for the production of active pharmaceutical ingredients (APIs) serves as a significant restraint that could impede the market's growth.

Market Trends

The cost incurred by the nation's healthcare system due to heart disease is on the rise. An important trend observed in the pharmaceutical intermediates market is the increasing prevalence of chronic cardiovascular conditions like heart failure and coronary artery disease. A July 2020 paper published in the Curious Journal of Medical Science states that ischemic heart disease (IHD) ranks as the leading cause of death worldwide. Approximately 126 million people globally are affected by ischemic heart disease. The projections indicate that by 2030, there will be over 1,845 cases of ischemic heart disease per 100,000 individuals worldwide.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Pharmaceutical Intermediates Market by Product

• Market Overview
• Chemical intermediates
• Bulk drug intermediates
• and Custom intermediates

Global Pharmaceutical Intermediates Market by Application

• Market Overview
• Analgesics
• Anti-inflammatory drug
• Cardiovascular drugs
• Anti-diabetic drugs
• Anti-cancer drugs

Global Pharmaceutical Intermediates Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• BASF SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dishman Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Codexis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikal Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chemcon Speciality Chemicals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Porton Fine Chemicals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Divis Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer CentreOne
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lianhe Chemical Technology Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shandong Xinhua Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi STA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang NHU Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments